Z20.2 Insurance Policy Changes

ICD-10 Z20.2 is officially defined as "Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission." code Z20.2 is referenced in 4 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z20.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Sep 29, 2026Medium impact
Orthopoxvirus Vaccines (CPB 0644, reviewed 2026-09-25)
Aetna considers pre-exposure smallpox vaccination medically necessary when public health authorities advise it, for research laboratory personnel who work with orthopoxviruses, clinical laboratory personnel performing orthopoxvirus diagnostic testing, designated response team members at risk for occupational exposure, and healthcare personnel who administer ACAM2000 or care for persons infected with orthopoxviruses. Booster doses are covered for persons with ongoing occupational exposure to orthopoxviruses in accordance with CDC recommendations, and post-exposure smallpox vaccination is covered for persons exposed or at high risk of exposure during a public health response. Mpox vaccination with JYNNEOS is medically necessary for pre-exposure use in listed higher-risk groups and for post-exposure use in persons with known or presumed mpox exposure, and routine smallpox vaccination of the general population is not recommended.
Aetna · Identified Aug 19, 2026Medium impact
Infectious Diseases: Selected Tests (CPB 1008, reviewed 2026-01-14)
This Aetna policy addresses metagenomic next-generation sequencing, multiplex immunoassay tests, molecular syndromic panels and other tests for infectious diseases that do not fit in other bulletins. RT-QuIC is considered medically necessary for evaluating individuals with rapidly progressive dementia suspected of prion disease, and syphilis non-treponemal and treponemal tests are considered medically necessary for screening all pregnant women and persons at risk of syphilis, and for diagnostic testing of individuals with signs and symptoms of syphilis. Aetna considers named tests such as the Karius Test, IntelliSep, MeMed BV, TriVerity and the Synovasure Comprehensive PJI Test Panel experimental, investigational or unproven.
Aetna · Identified Aug 17, 2026Medium impact
Hepatitis Screening (CPB 0835, reviewed 2025-12-09)
Aetna considers hepatitis B screening medically necessary for listed groups, including people on hemodialysis, blood or organ donors, pregnant women, people with HIV, injection drug users, men who have sex with men, and people born in regions with a 2% or higher HBV prevalence. Hepatitis C screening is medically necessary for listed groups, and one-time HCV testing without prior risk assessment is medically necessary for adults aged 18 years and older. Hepatitis D screening is medically necessary for people with HBsAg-positive hepatitis B infection and significant risk factors, while hepatitis E screening in the peri-transplant period is experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Orthopoxvirus Vaccines (CPB 0644, reviewed 2025-12-15)
Aetna considers orthopoxvirus vaccines medically necessary for the listed smallpox and mpox indications when the policy criteria are met, and routine smallpox vaccination of the general population is not recommended. Listed smallpox indications are pre-exposure vaccination for research laboratory personnel working with orthopoxviruses, clinical laboratory personnel performing diagnostic testing for orthopoxviruses, designated response team members at risk for occupational exposure, and healthcare personnel who administer ACAM2000 or care for persons infected with orthopoxviruses, along with JYNNEOS boosters for ongoing occupational exposure and post-exposure vaccination during a public health response. Listed mpox indications are pre-exposure vaccination for persons with known or presumed exposure to mpox virus or a sex partner diagnosed with mpox in the previous 14 days, and post-exposure JYNNEOS vaccination for persons with known or presumed exposure to mpox virus.

Watch Z20.2

Get one email when a payer policy names Z20.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z20.2?

There are 4 tracked policy changes affecting code Z20.2, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z20.2?

Payers that have issued tracked updates for code Z20.2 include: Aetna.

How do I get notified when code Z20.2 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z20.2. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z20.2?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Orthopoxvirus Vaccines (CPB 0644, reviewed 2026-09-25)

Infectious Diseases: Selected Tests (CPB 1008, reviewed 2026-01-14)

Hepatitis Screening (CPB 0835, reviewed 2025-12-09)

Orthopoxvirus Vaccines (CPB 0644, reviewed 2025-12-15)

What insurance policy changes affect code Z20.2?

Which payers have updated policy for code Z20.2?

How do I get notified when code Z20.2 policy changes?

Why do payers change policies for code Z20.2?